BBB National Programs Decision Summaries
BBB National Programs provides summaries of all case decisions from the National Advertising Division (NAD), National Advertising Review Board (NARB), Children’s Advertising Review Unit (CARU), Direct Selling Self-Regulatory Council (DSSRC), and Digital Advertising Accountability Program (DAAP). Subscribe to receive a weekly wrap-up of published case decisions in your inbox.
- All
-
6/14/2019 - NAD Finds GlaxoSmithKline’s Sensodyne Toothpaste “#1 Dentist Recommended Brand” Claims Supported; No Additional Disclosures Necessary
The National Advertising Division has concluded that GlaxoSmithKline Consumer Healthcare provided a reasonable basis for its “#1 Dentist Recommended Brand” and “9 out of 10 dentists recommend Sensodyne” claims for its Sensodyne brand of toothpaste, and that no additional qualification or material information is necessary, following a challenge by Colgate-Palmolive Company, maker of competing sensitive and general toothpaste products. -
6/13/2019 - NAD Finds Reckitt Benckiser’s “#1 Carpet Cleaning Brand” Claim Supported; Recommends Modification to Disclaimer
The National Advertising Division has found that Reckitt Benckiser, Inc.’s “#1 Carpet Cleaning Brand” claim for its Resolve Carpet Cleaner products is properly supported by unit sales data, following a challenge by BISSELL Homecare, Inc. However, NAD recommended modification to the disclaimer accompanying the claim to identify the time period for the claim and its scope. -
6/13/2019 - CARU Recommends JAKKS Pacific Modify Broadcast Advertising to Better Disclose that Dolls Do Not Move on Their Own
The Children’s Advertising Review Unit has recommended that JAKKS Pacific, Inc., modify broadcast advertising for the Winx Club Harmonix Dolls to better to disclose to a child audience that the dolls do not move on their own. -
6/12/2019 - NARB Recommends Chattem Discontinue Certain Claims for ACT Dry Mouth Mouthwash and ACT Dry Mouth Lozenges; Approves Others
A panel of the Advertising Review Board (NARB) has recommended that Chattem, Inc. discontinue certain advertising claims for ACT Dry Mouth Mouthwash and ACT Dry Mouth Lozenges, while also approving others. The advertising at issue had been challenged by GlaxoSmithKline Consumer Healthcare, L.P., the manufacturer of the competing Biotene brand oral care products, before the National Advertising Division (NAD). The NAD is an investigative unit of the advertising industry’s system of self-regulation administered by the Council of Better Business Bureaus. Following the NAD’s decision, Chattem appealed certain recommendations made by NAD to the NARB, the appellate unit of the advertising industry’s system of self-regulation. GSK exercised its right under the applicable rules of procedure to file a cross-appeal. -
6/11/2019 - NARB Recommends AT&T Modify or Discontinue One Advertisement, Approves Another, in its “More For Your Thing – That’s Our Thing” Campaign, Following T-Mobile Challenge
A panel of the National Advertising Review Board (NARB) has found that an AT&T Services Inc. internet advertisement claiming “More for Your Stream Like a Boss Thing” conveys an unsupported superiority claim comparing AT&T to its competitors, and recommended that it be modified or discontinued. In the same proceeding, NARB found in favor of AT&T with regard to its “Do Your Thing” commercial. -
5/22/2019 - Self-Regulatory Unit, Prompted by Consumers, Brings Ad Tech Companies into Full Compliance with Privacy Principles
The Online Interest-Based Advertising Accountability Program, an independent enforcer of the Digital Advertising Alliance’s self-regulatory Principles, released the results of inquiries into two advertising technology companies. -
5/21/2019 - NAD Refers Puerto Rico Telephone Company Advertising to FTC After Advertiser Declines to Participate; Claims Challenged by AT&T
The National Advertising Division has referred advertising claims made by Puerto Rico Telephone Company to the Federal Trade Commission for further review after the company declined to participate in a proceeding before NAD. -
5/13/2019 - In Response to NAD Inquiry, Maker of Vayarin Dietary Supplement Says Product has Been Discontinued and Company has Closed
VAYA Pharma, Inc., the U.S. manufacturer and supplier of Vayarin, a dietary supplement marketed for the management of ADHD, has advised the National Advertising Division that the product has been discontinued and it has closed its business. -
5/13/2019 - NAD Finds “All In One” Claim Adjacent to Symptom List on Mucinex Label Not Misleading; Recommends Other Changes
The National Advertising Division has found that Reckitt Benckiser, Inc.’s “All in One” claim when positioned adjacent to a list of symptoms treated by its Maximum Strength Mucinex Fast-Max Cold & Flu both on the product label and in a 30-second does not convey the misleading message that the product treats all cold and flu symptoms in one product, following a challenge by The Procter & Gamble Company, the maker of Vick’s DayQuil/Nyquil medications. However, NAD recommended discontinuation of other challenged advertisements. -
5/09/2019 - NARB Recommends Eli Nutrition Discontinue Certain Antacid Claims Made for TummyZen Dietary Supplement, Approves Other Claims
A panel of the National Advertising Review Board (NARB) has recommended that Eli Nutrition, Inc. discontinue certain advertising claims (while also approving others) made on product packaging and in online advertising for Eli Nutrition’s TummyZen dietary supplement. TummyZen is an antacid containing calcium carbonate and zinc. The advertising at issue had been challenged by GlaxoSmithKline Consumer Healthcare, L.P., which sells Tums, before the National Advertising Division (NAD). The NAD is an investigative unit of the advertising industry’s system of self-regulation administered by the Council of Better Business Bureaus. Following the NAD’s decision, Eli Nutrition appealed to the NARB, the appellate unit of the advertising industry’s system of self-regulation.